MPP collaborates with the University of Liverpool to develop HIV nanomedicines

The Medicines Patent Pool (MPP) has entered a collaboration with the University of Liverpool, UK, and a licence for the university’s Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines.

The agreement covers a territory of all 135 low- and middle-income countries and two high-income countries in Africa, where licensees based anywhere in the world will have the right to make, use and distribute lower cost ARVs based on SDN technology.

“With the World Health Organization’s ‘treat-all’ recommendations, more than 20 million people are still in need of viable, sustainable treatment options,” said Greg Perry, executive director of the MPP, adding: “This partnership seeks to help meet new international HIV scale-up targets through the delivery of better-adapted low-dose medicines at a significant price reduction.”